Clinical Pharmacokinetics of the Newer Benzodiazepines

David J. Greenblatt; Marcia Divoll; Darrell R. Abernethy; Hermann R. Ochs; Richard I. Shader

doi:10.2165/00003088-198308030-00003

Clinical Pharmacokinetics of the Newer Benzodiazepines

David J. Greenblatt, Marcia Divoll, Darrell R. Abernethy, Hermann R. Ochs, Richard I. Shader

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.

Original language	English (US)
Pages (from-to)	233-252
Number of pages	20
Journal	Clinical Pharmacokinetics
Volume	8
Issue number	3
DOIs	https://doi.org/10.2165/00003088-198308030-00003
State	Published - Jun 1983
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.2165/00003088-198308030-00003

Cite this

@article{c3dbb1c81e884867935136b4a978de86,

title = "Clinical Pharmacokinetics of the Newer Benzodiazepines",

abstract = "New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.",

author = "Greenblatt, {David J.} and Marcia Divoll and Abernethy, {Darrell R.} and Ochs, {Hermann R.} and Shader, {Richard I.}",

year = "1983",

month = jun,

doi = "10.2165/00003088-198308030-00003",

language = "English (US)",

volume = "8",

pages = "233--252",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - Clinical Pharmacokinetics of the Newer Benzodiazepines

AU - Greenblatt, David J.

AU - Divoll, Marcia

AU - Abernethy, Darrell R.

AU - Ochs, Hermann R.

AU - Shader, Richard I.

PY - 1983/6

Y1 - 1983/6

N2 - New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.

AB - New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.

UR - http://www.scopus.com/inward/record.url?scp=0020536610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020536610&partnerID=8YFLogxK

U2 - 10.2165/00003088-198308030-00003

DO - 10.2165/00003088-198308030-00003

M3 - Article

C2 - 6133664

AN - SCOPUS:0020536610

SN - 0312-5963

VL - 8

SP - 233

EP - 252

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

IS - 3

ER -

Clinical Pharmacokinetics of the Newer Benzodiazepines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this